RGENTA THERAPEUTICS
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
RGENTA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rgentatx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
56.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Similar Organizations
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Seed Round - Rgenta Therapeutics
Kaitai Capital
Kaitai Capital investment in Seed Round - Rgenta Therapeutics
Vivo Capital
Vivo Capital investment in Seed Round - Rgenta Therapeutics
Matrix Partners China
Matrix Partners China investment in Seed Round - Rgenta Therapeutics
Legend Star
Legend Star investment in Seed Round - Rgenta Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - Rgenta Therapeutics
Kaitai Capital
Kaitai Capital investment in Seed Round - Rgenta Therapeutics
Official Site Inspections
http://www.rgentatx.com Semrush global rank: 4.33 M Semrush visits lastest month: 2.64 K
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Rgenta Therapeutics"
Rgenta Therapeutics | Rgenta Therapeutics
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.See details»
Science | Rgenta Therapeutics
At Rgenta, we develop novel methods to mine the wealth of genomics data to identify high-efficacy and high-specificity RNA target sites. We also build focused compound libraries likely to recognize the RNA target sites and modulate their …See details»
Rgenta Therapeutics - Crunchbase Company Profile
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and …See details»
Rgenta Therapeutics Inc. - LinkedIn
We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecules. Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting...See details»
Contact | Rgenta Therapeutics
For general information contact us at [email protected]. Follow us on LinkedIn. Rgenta Therapeutics is a biotechnology start-up focused on the development of oral RNA-targeting …See details»
Rgenta Therapeutics | Leukemia and Lymphoma …
Jan 30, 2024 · For more information about Rgenta, visit rgentatx.com. Recent News July 10, 2024 - announced the IND clearance for RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma …See details»
Rgenta Therapeutics Announces the Successful Completion of …
May 25, 2021 · Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at http://www.rgentatx.com. …See details»
Rgenta Therapeutics Company Profile 2024: Valuation, …
Developer of a data-driven mRNA target identification platform intended to develop RNA-targeting medicines.See details»
Rgenta Therapeutics recipient of the Servier’s 2020
Potential of historically undruggable targets in human diseases. Learn more at http://www.rgentatx.com. Press contact: Rgenta Therapeutics: [email protected]See details»
Rgenta Therapeutics Launches with $20 Million Seed Investment
Apr 2, 2020 · Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.See details»
Team | Rgenta Therapeutics
Heather comes to Rgenta with 16 years of drug discovery experience in both a successful start-up and an international pharmaceutical setting. Prior to Rgenta, Heather was at Yumanity Therapeutics where she led the Target Discovery …See details»
Rgenta Company Profile - Office Locations, Competitors, Revenue …
Rgenta Therapeutics is a company developing RNA-targeting medicines focused on oncology and neurological disorders. Its platform mines genomics data to identify targetable RNA processing …See details»
Rgenta Therapeutics Raises $52M in Series A Financing
Nov 29, 2022 · Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at https://www.rgentatx.comSee details»
Rgenta Therapeutics Announces Formation of Repeat Expansion …
Jun 21, 2023 · Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at http://www.rgentatx.com. …See details»
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society …
Jan 30, 2024 · Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration …See details»
News | Rgenta Therapeutics
WOBURN, Mass., October 8, 2024 — Rgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for …See details»
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society
Jan 30, 2024 · Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at www.rgentatx.com. About …See details»
Join Us | Rgenta Therapeutics
We believe our programs are powered by innovative technology and exceptional people. We are rooted in our leadership team’s deep drug discovery experience and successful track record. …See details»
Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b ...
Oct 8, 2024 · Rgenta's Phase 1a/b clinical trial of RGT-61159 is a multi-center, open-label study dose escalation and expansion study in patients with advanced relapsed or refractory ACC or …See details»
Online payment @ RD
Online payment. Please enter any details in the notes section. Enter Amount *. NotesSee details»